Compare Crown Castle International Corp (CCI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Summit Therapeutics Inc — how do they compare? Crown Castle International Corp trades at $73.76 (market cap $31.47B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Crown Castle International Corp is far larger — about 2.6× Summit Therapeutics Inc's market cap, and Crown Castle International Corp pays a 5.75% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CCI | SMMT | |
|---|---|---|
Market Cap | $31.47B | $12.06B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $26.98 |
52-Week Low | $73.61 | $12.55 |
Enterprise Value | $53.83B | $11.39B |
Dividend Yield | 5.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $73.98, near 52-week lows, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 AFFO of $1.13 per share, beating estimates, and raised full-year guidance amid its transition to a pure-play U.S. tower operator. Revenue declined to $4.26B in 2025 but profitability improved with 20.72% net margin. Analyst consensus remains divided with 50% buy ratings and $95.29 price target suggesting 29% upside.
The stock presents a value opportunity with discounted valuation and 5.5% dividend yield, but faces headwinds from high debt levels (77.21% debt-to-asset ratio) and competitive pressure in the tower REIT sector. Recent institutional selling and technical weakness indicate near-term caution despite long-term growth potential from wireless infrastructure demand.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
